Last updated: 2026-09-06 20:23:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Opus Genetics, Inc. (IRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.66, with a market capitalization of $370.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.24 to $5.81. This page covers its latest market performance, valuation, price trends and company information.
$370.22M | |
$4.53 | |
$5.81 | |
$0.65 | |
$4.60 | |
2.09M | |
-- | |
-- | |
$5.81 | |
$1.24 | |
-- | |
-- |
Opus Genetics, Inc. (IRD) last closed at $4.60 as of 2026-09-04 23:34:00, unchanged from the previous close of $4.60.
During the latest regular trading session, IRD traded between $0.65 and $5.81, with a volume of 2.09M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Opus Genetics, Inc. (IRD) moved from $3.71 to $4.66, representing a gain of 25.66% ($0.95).
The stock traded between $4.42 and $4.78 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.07 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.9%
IRD is currently trading at $4.66, placing it 74.9% of the way from its 52-week low of $1.24 to its 52-week high of $5.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Opus Genetics, Inc. (IRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.